Securities Class Action Risks in Digital Health Firms: A Deep Dive into Hims & Hers Health, Inc.

The digital health sector, once a beacon of innovation and growth, has become a hotbed for legal scrutiny. At the center of this storm is Hims & Hers Health, Inc., a company that epitomized the promise of telehealth—until a securities class action lawsuit exposed vulnerabilities in its business model. This case, Sookdeo v. Hims & Hers Health, Inc., offers a masterclass in how legal timelines and investor accountability intersect in the high-stakes world of digital health.

The Catalyst: A Partnership Gone Wrong

Hims & Hers' troubles began with a high-profile collaboration with Novo Nordisk A/S, the maker of Wegovy®, an FDA-approved weight-loss drug. From April 29 to June 23, 2025—the so-called “Class Period”—the company marketed Wegovy® through its platform while allegedly selling unapproved “knockoff” versions of the drug.

.

The fallout was swift. On June 23, 2025, Novo Nordisk terminated the partnership, citing deceptive practices. Hims & Hers' stock plummeted by over 34% in a single day, erasing billions in market value. The lawsuit alleges that executives knew of the risks but failed to disclose them, violating the Private Securities Litigation Reform Act of 1995 (PSLRA).

Legal Timelines: A Race Against the Clock

The PSLRA mandates that investors seeking to lead the class action must file motions by August 25, 2025. This deadline is critical: the lead plaintiff must demonstrate the largest financial loss and representative claims. While many investors may opt to remain passive class members, the lead plaintiff's role is pivotal in shaping the litigation's trajectory.

The legal framework requires plaintiffs to prove material misrepresentation, scienter (intent or recklessness), and loss causation. Hims & Hers' case hinges on whether the company's actions directly caused the stock's collapse. The termination of the Novo Nordisk partnership—a public admission of misconduct—strengthens the plaintiffs' argument.

Investor Accountability: Lessons for the Digital Health Sector

The Hims & Hers case underscores a broader issue: the tension between innovation and regulation in digital health. Startups in this sector often prioritize rapid growth over compliance, creating a fertile ground for securities fraud. Investors must now ask: How do we balance the allure of disruptive tech with the need for accountability?

For investors, the takeaway is clear:
1. Due Diligence is Non-Negotiable: Scrutinize partnerships and product claims, especially in unregulated areas like telehealth.
2. Monitor Legal Deadlines: The lead plaintiff process is a window of opportunity to influence outcomes. Missing August 25, 2025, could mean ceding control to less informed investors.
3. Diversify Exposure: Avoid overconcentration in companies with high regulatory risk.

The Road Ahead: What's Next for Hims & Hers?

As the case progresses, the court will weigh the plaintiffs' ability to prove that Hims & Hers' executives acted with scienter. If successful, the lawsuit could set a precedent for holding digital health firms accountable for misleading marketing. However, even a favorable ruling may not restore investor trust—a commodity Hims & Hers has already squandered.

For the broader sector, this case is a wake-up call. The line between innovation and deception is thin, and investors must demand transparency. As one of the most prominent law firms in the case, Robbins Geller Rudman & Dowd LLP, has noted: “The digital health boom cannot come at the expense of investor protection.”

Final Thoughts

The Hims & Hers saga is a microcosm of the risks and rewards in digital health. While the sector's potential is undeniable, its legal and ethical challenges cannot be ignored. Investors must remain vigilant, leveraging tools like the PSLRA to hold companies accountable. In the end, accountability—not just innovation—will define the future of this industry.

For those watching the case closely, the August 25 deadline is a pivotal moment. Whether you choose to lead the charge or ride the wave of the class action, the message is clear: in the digital health arena, the stakes are high, and the rules of the game are being rewritten.